MassDebater
Recently Joined
Regarding the dosage of Tesamorelin, the standard reference for its efficacy is the Phase III clinical trials published by Falutz et al. (2010) in the New England Journal of Medicine, which concluded that the 2mg daily dose is the threshold required for statistically significant reductions in visceral fat. However, these findings are based solely on the administration of Tesamorelin as a monotherapy. Since GHRH compounds are inherently limited by somatostatin activity, and because GHS compounds like Ipamorelin are known to significantly inhibit somatostatin, could the same statistically significant effects of a 2mg dose from tesa be achieved with only 0.5mg or 1mg if stacked with a "decent" enough dose from Ipamorelin? I primarily ask this question because much of the anecdotal evidence from users stacking 2mg of Tesamorelin with 300mcg (or other significant doses) of Ipamorelin describes the experience as 'overwhelming' in terms of side effects and intensity. From this anecdotal "suggestion", I would assume that Ipamorelin likely upregulates the body's response to Tesamorelin, potentially allowing for a lower, more efficient dose to achieve the same elevated growth hormone levels.